New Target for Minoxidil in the Treatment of Androgenetic Alopecia
Yuqing Shen,Yuqi Zhu,Li Zhang,Jiayi Sun,Bo Xie,Hongyan Zhang,Xiuzu Song
DOI: https://doi.org/10.2147/DDDT.S427612
2023-08-24
Abstract:Yuqing Shen, 1 Yuqi Zhu, 1 Li Zhang, 1 Jiayi Sun, 1 Bo Xie, 2 Hongyan Zhang, 2 Xiuzu Song 2 1 Department of Dermatology, Hangzhou Third People's Hospital, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China; 2 Department of Dermatology, Hangzhou Third People's Hospital, Affiliated Hangzhou Dermatology Hospital of Zhejiang University School of Medicine, Hangzhou, People's Republic of China Correspondence: Xiuzu Song, Hangzhou Third People's Hospital, Hangzhou, People's Republic of China, Email Objective: To investigate the mechanism of minoxidil in treating androgenetic alopecia (AGA). Methods: The mechanism of action of minoxidil on AGA was first systematically investigated from the viewpoint of network pharmacology, including minoxidil-AGA target prediction, protein-protein interaction (PPI) network analysis, molecular docking and enrichment analysis of targets related to minoxidil and AGA, and dermal papilla cell assays to confirm the viability of prediction. Results: The combined analysis revealed that minoxidil treatment of AGA not only acts on androgenic receptors (AR) but also on 2 new targets, steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1) and aromatase (CYP19A1). The biological processes linked to these targets were concentrated on several pathways, including enzymes and hormones. Further experiments have revealed that minoxidil suppresses the expression of AR and CYP17A1, boosts the activity of CYP19A1, decreases the formation and binding of dihydrotestosterone, and enhances the production of estradiol. Through these changes, minoxidil acts as a treatment for AGA. Conclusion: Minoxidil may act by altering hormonal and enzymatic pathways. Our study finds two new targets (CYP17A1, CYP19A1) of minoxidil and demonstrates that minoxidil inhibits AR. These targets may provide new ideas for drug research. Keywords: minoxidil, androgenetic alopecia, targets Androgenetic alopecia (AGA) is the most frequent kind of clinical alopecia, accounting for 95% of all hair loss, and is characterized by symmetrical progressive hair thinning. 1,2 Minoxidil was approved for the topical treatment of AGA in 1988. 3 Many possibilities have been proposed, including activation of the Wnt/β-catenin signaling pathway in dermal papilla cell (DPC), 4 promotion of follicular epithelial cell proliferation and differentiation, prolongation of the follicular anagen phase, and facilitation of the conversion of vellus hair to terminal hair. Upregulation of vascular endothelial growth factor (VEGF) mRNA and protein expression in DPC stimulates angiogenesis and increases local blood supply. 5 Opening potassium channels allows more potassium ions into the cell and prevents calcium ions from entering, lowering the inhibitory impact of the epidermal growth factor on hair development. 6 Minoxidil significantly reduces the expression of the IL-1 gene in human immortalized keratinocytes, probably via slowing the inflammatory process of AGA. 7 In addition to the above effects, it has also been suggested that minoxidil effects are also related to sulfotransferase activity, and that minoxidil is only a prodrug that needs to be metabolised by follicular sulfotransferase to minoxidil sulfate (the active form) in order to be effective. 8 Although many possibilities have been suggested, the therapeutic mechanism of minoxidil in AGA is uncertain. Network pharmacology is a novel field based on building multi-layered networks of disease phenotypes, genes, and drugs to predict drug targets with a holistic view, allowing the discovery of additional mechanisms behind the disease. 9,10 It connects artificial intelligence with medicine and the analysis of massive biomedical data, allowing the transformation of data completion into knowledge. Our curiosity about the causes of hair loss and the rejuvenating benefits of minoxidil on hair growth has been awakened. In this study, network pharmacology—which includes drug target prediction, network analysis, and experimental validation—was used to study the effects of minoxidil on AGA. In-depth studies on the mechanism of action of minoxidil may identify new therapeutic targets and provide new ideas for the development of new drugs. We wanted to obtain more potential target proteins for minoxidil and searched different databases (SwissTargetPrediction, DrugBank, and PharmMapper); we limited the species to "Homo sapiens". Cytoscape software visualizes the relationship between minoxidil and target proteins, with nodes representing minoxidil and target proteins and edges representing their interaction. 11 A search of the Genecar -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal